Michael Kauffman
CIK 1364719 · President of Development · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KPTI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
85 WELLS AVENUE, SECOND FLOOR
NEWTON, MA 02459
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYNB | Director | — | $4.53 | — | $0 | 1 | 2026-06-17 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 0 | $7.29 | $0 | -$82.2K | 11 | 2026-05-11 |
| VSTM | President of Development | 8,666 | $9.91 | $85.9K | -$51.8K | 19 | 2026-01-08 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | — | $9.75 | — | $0 | 1 | 2025-06-06 |
| NCNA | Director | — | $1.09 | — | $0 | 1 | 2024-08-23 |
| ACET | Director | 738 | $3.88 | $2.9K | -$8.4K | 5 | 2024-06-07 |
| KPTI | Chief Executive Officer | 107,874 | $0.44 | $47.3K | -$19.88M | 64 | 2022-03-02 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-06-14 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Chief Medical Officer | 9,000 | — | — | $0 | 2 | 2010-02-11 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Director | — | — | — | $0 | 3 | 2010-01-20 |
| BIOENVISION INC (BIVN) Delisted | Director | — | — | — | $0 | 1 | 2007-01-05 |
Recent Filings · Page 10 of 12
117 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-12-20 | KPTI | Mixed | — | -$88.9K | EDGAR |
| 2017-12-08 | KPTI | Mixed | — | -$101.3K | EDGAR |
| 2017-06-15 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2017-04-06 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-24 | KPTI | Grant (A) | — | $0 | EDGAR |
| 2016-06-16 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2016-02-17 | VSTM | Sell (S) | −3,000 | -$23.6K | EDGAR |
| 2016-01-20 | KPTI | Grant (A) | — | $0 | EDGAR |
| 2015-06-16 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2015-01-22 | KPTI | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.